ABSTRACT
Introduction
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality woldwide. The disease is a chronic, progresive inflammatory airway disease. There has been increasing evidence about it's systemic manifestations. [1, 2] Systemic inflammation associated with airway inflammation accounts for extrapulmonary effects of COPD. It has been reported that levels of systemic inflammotory markers like hs-CRP, fibrinogen and IL-6 are higher in patients with COPD. [3] COPD is associated with various clinically significant systemic problems like cardiovascular diseases. It has been proposed that these comorbidities do not just result from the effect of smoking but systemic inflammation may also be responsible for extrapulmonary manifestations. [4] Metabolic syndrome (MS) is characterized by a group of risk factors (abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance) that induces the development of several diseases such as coronary artery disease. [5, 6] It is a condition that predisposes systemic inflammation, Previous studies showed that the prevalence of MS is increased in COPD patients. [3, 7] Erectile function is an important factor for quality of life and psycological status of males in male patients. Erectile dysfunction (ED) may worsen the depressive mood which is seen frequently in COPD patients. In previous studies, varying degrees of ED was detected in COPD patients and it was reported that ED is more prevalent in COPD patients than general population. [8, 9] The aim of the this study is to evaluate the effects of MS on the frequency and severity of ED and to investigate the factors influencing severity of ED in COPD patients.
Materials and Method
One hundred forty male patients with stable COPD and 80 age-matched control subjects were included in the study. This study was approved by the ethics committee of our institution, and informed consent was obtained from all participants. Spirometry was performed to all of the participants by using VIASYS Healthcare V max ® 20 Pulmonary Spirometry Instrument. Severity of COPD was determined according to Global Initiative for Obstructive Lung Disease (GOLD). [10] Diagnosis of MS was made by using The National Cholesterol Education Program's Adult Treatment Panel (ATP) III (Table 1) . [11] Patients and control subjects who have been using any medication which might interfere with serum hormone levels and patients who had a malignant disease or endocrine, neurologic disturbances that might affect erectile function were excluded from the study.
A venous blood sample was collected from each subject after a 12-hour fasting. Plasma glucose, triglyceride (TG), high density lipoprotein (HDL) were measured by using a Roche COBAS INTEGRA ® 400 plus analyzer by an enzymatic calorimetric assay. Sex hormones (total testosterone, free testosterone), gonadotrophic hormones [Follicle stimulating hormone (FSH), Luteinizing hormone (LH)] were measured by Roche Elecsys 2010 with electrochemiluminesence immunoassay. Hematocrit (htc) levels were measured after hemogram evaluation by using Beckman Coulter LH 780 instrument. If the participants were using antihypertensive or antidiabetic drugs , they were considered to have high blood pressure or high fasting glucose respectively. C-reactive protein (CRP) levels were measured by using a Roche COBAS INTEGRA ® 400 plus analyzer by automatic calorimetric assay.
International Index of Erectile Function (IIEF) questionnaire was performed to all participants to diagnose and to grade the severity of ED by an urologist. The IIEF scores ranged from 1 to 25. According to the National Institutes of Health criteria the severity of ED was graded as follows: 1-7 severe ED, 8-11 moderate ED, 12-16 mildmoderate ED, 17-21 mild ED and 22-25 normal erectile function. [12, 13] Patients with ED were divided into two groups; group I consisted of patients with severe to moderate ED, and group II consisted of patients with mild, mild-moderate ED to normal erectile function. Control subjects were also divided into two groups as group 3 and group 4 respectively as described above.
Arterial blood gas analysis (ABG) of COPD patients were made by Gem Premier 3000 blood gas/ electrolyte analyzer model 570, interpreted as follows; pH<7.35:asidosis, 7.35-7.45: normal; pCO2>45 mmHg: hypercapnia, 35-45 mmHg: normocapnia, pO2≥80 mmHg: normal, <80 mmHg: hypoxemia. Hypoxemia was graded as mild for pO2; 60-80 mmHg, moderate;40-59 mmHg and severe <40 mmHg. [14] 
Statistical Analysis
Statistical analyses were carried out with SPSS for Windows version 15.0 statistical software (SPSS Inc., Chicago, IL, USA). Continuous variables were presented as mean±standard deviation or median [min-max] and cate-gorical variables as frequencies and percentages. In order to establish the normality, distributions of the numeric variables were examined by Kolmogorov-Smirnov test. For numeric variables, differences between the groups were determined by independent samples t test or Mann Whitney test. Chi square test was used to determine the associations between categorical variables. Significance value was considered as 0,05.
Results
Mean ages of COPD patients and control group were 70.15±8.9 years and 71.48±5.6 years respectively. All of the COPD patients and most of the control group (%86.2) had a history of smoking (current or ex smoker). There was no statistically significant difference in terms of age and history of smoking between the two groups (p>0.05). Free testosterone levels were lower and FSH levels were higher in patients with COPD than that of control group (p<0.005, p<0.0001, respectively). Htc levels were significantly lower in COPD patients than those obtained from control subjects (p<0.05). Mean levels of sex hormones and gonadotrophic hormone levels and htc are shown in table 2.
All of the COPD patients (100%) and 68% of control subjects had varying degrees of ED. In patients with COPD 67.1% of the patients (n=94) were in group one, and 32.8% of patients (n=46) were in group 2. Only 6.2 % of the control subjects (n=5) were in group 3, and the rest of the control group (93.8%) were in group 4. Severity of ED was significantly worse in COPD group than the control group (p<0.0001) (Figure 1) . The distribution of patients considering GOLD stages was as follows; stage MS frequency was 55% in COPD patients, and 31% in control group. There was significant difference between the two groups (p<0.05). The frequency of MS was higher in group 1 than group 2 ( 67% vs 30.8%) (p<0.05).
Mean age of patients in group 1 was higher than group 2 (73.2±7.8 years vs 63.6±7.6years) (p<0.005). There was no statistically significant difference between group 1 and group 2 with respect to the presence and absence of respiratory asidosis, hypercapnia, hypoxemia and severity of hypoxemia. Levels of htc in both groups were almost the same ( p>0.05 for all) ( Table 3) . Table 3) .
Discussion
This study showed that not only the frequency but also the severity of ED was significantly higher in patients with COPD than control group. The severity of ED did not differ between GOLD stages.The frequency of MS was higher among COPD patients who had more severe ED. Our study showed that ED is frequent and more severe in COPD patients than age-matched controls. This result is compatible with the results of a previous study that was reported by Karadağ et al. [9] . Köseoğlu et al. reported that severity of ED was suitable with severity of COPD stages. Although that study did not have a control group, ED prevalence was found higher than general population. [8] In our study, severity of ED did not show correlation with COPD stages, but prevalence of ED was higher than the control group and also than the results of the study by Köseoğlu et al. (100% vs 75.5%). [8] As far as we are concerned this is the first study in the literature which evaluates the effect of MS on presence and severity of ED. In a former study, the frequency of co-morbid conditions accompanying COPD like coronary artery disease and hypertension were reported, but neither the prevelance of MS nor its affect on severity of COPD was evaluated. [8] In our study the prevalence of MS in patients with COPD is found higher than the study by Watz et al. in which COPD patients from both gender with a majority of males were included (55% vs 47.5%). [7] On the other hand our prevelance is lower than male COPD patients who participated in a cardiopulmonary program (55% vs 61%). [6] The later difference may be a result of the patient population as they were participants in a cardiopulmonary program and were likely to have MS components like hyperlipidemia, hypertension and abdominal obesity. Since all of the COPD patients who were participated in this study had varying degrees of ED, prevalence of MS in patients who had ED was also the same (55%). The MS prevelance was found to be lower in control group (55% vs 31%).
Prevalence of MS in patients who had more severe ED was higher than patients who had less severe ED (67% vs 30.8%). Our study confirms that increasing age effects the severity of ED. It has been suggested that TNF-α levels as a marker of systemic inflammation are higher in patients with COPD who had more severe ED [9] . In our study, although CRP levels (as a marker of systemic inflammation) of COPD patients are found to be higher than the control group, results showed that severity of ED and presence of MS are not affected by CRP levels. It has been proposed that hypoxia may cause vasoconstruction in penile circulation and underlined that further studies are needed to understand the role of chronic hypoxia on the development of ED. [15] It is well-known that hypercapnia and respiratory asidosis cause pulmonary vasoconstruction while increasing cardiac output and sympathetic tone by the effect on central nervous system. [16] But it's role in gonadal vasculature is still unknown. We propose that presence of hypoxia, hipercapnia, respiratory asidosis and severity of hypoxia does not affect the severity This study has some limitations; Firstly, this was a unicentric study that was performed in a university hospital which is a third step healyh care service. So, study population may not be representative for all COPD patients in the country. Secondly, it was concluded that although all COPD patients who participated in the study had varying degrees of ED, the prevelance of MS was higher in patients who had more severe ED. However, the relationship between presence of MS and ED was not clarified.
The current study showed that ED is an important comorbidity of male COPD patients, that had been overlooked before. Age is found to be a factor which is effective on severity of ED in COPD patients. MS was more prevelant in COPD patients, especially in those who had more severe ED. However, as a systemic inflammatory marker, serum CRP levels did not differ between patients who had varying degrees of ED and ones with or without MS. Further, larger population-based studies are needed to clarify the effect of MS on presence and severity of ED. The exact mechanism of MS in the development of ED in patients with COPD should also be investigated. We proposed that the presence of ED should be evaluated in male COPD patients and it should be kept in mind that the severity of ED may increase when MS accompanies COPD.
